These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7089477)

  • 1. Iron overload in a non-transfused patient with thalassaemia intermedia.
    Celada A
    Scand J Haematol; 1982 Feb; 28(2):169-74. PubMed ID: 7089477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.
    Garbowski MW; Evans P; Vlachodimitropoulou E; Hider R; Porter JB
    Haematologica; 2017 Oct; 102(10):1640-1649. PubMed ID: 28642302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
    Taher A; Hershko C; Cappellini MD
    Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption of inorganic and food iron in children with heterozygous and homozygous beta-thalassemia.
    Heinrich HC; Gabbe EE; Oppitz KH; Whang DH; Bender-Götze C; Schäfer KH; Schröter W; Pfau AA
    Z Kinderheilkd; 1973 Aug; 115(1):1-22. PubMed ID: 4796508
    [No Abstract]   [Full Text] [Related]  

  • 8. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron absorption and loading in beta-thalassaemia intermedia.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1979 Oct; 2(8147):819-21. PubMed ID: 90918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB; Garbowski MW
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
    Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma neutrophil gelatinase-associated lipocalin levels are markedly increased in patients with non-transfusion-dependent thalassemia: Lack of association with markers of erythropoiesis, iron metabolism and renal function.
    Patsaoura A; Tatsi E; Margeli A; Kanavaki I; Delaporta P; Kyriakopoulou D; Kouraklis-Symeonidis A; Kattamis A; Papassotiriou I
    Clin Biochem; 2014 Aug; 47(12):1060-4. PubMed ID: 24721683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac abnormalities in the thalassaemia syndromes.
    Yee H; Mra R; Nyunt KM
    Southeast Asian J Trop Med Public Health; 1984 Sep; 15(3):414-21. PubMed ID: 6523177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
    Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM; Cappellini MD; Wood JC; Taher AT
    Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia.
    Cazzola M; Borgna-Pignatti C; de Stefano P; Bergamaschi G; Bongo IG; Dezza L; Avato F
    Scand J Haematol; 1983 Apr; 30(4):289-96. PubMed ID: 6857145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
    Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High transfusion treatment of a case of thalassaemia major.
    Modell CB
    Trans R Soc Trop Med Hyg; 1967; 61(2):174-7. PubMed ID: 6047752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.